...

After the administrative transition of the DBS from the NIH to the Food and Drug Administration (FDA) in 1972, Parkman stayed on. He became the deputy director of what was then called the FDA Bureau of Biologics in 1973, a position he held until 1982, moving to the first floor of Building 29. In the 1980s, biologics underwent a series of organizational and name changes at the FDA. From 1982 to 1984 he was the scientific director of the FDA National Center for Drugs and Biologics, and from 1984 to 1987, Parkman was the deputy director at the FDA Center for Drugs and Biologics. In 1987, Parkman became director of the FDA Center for Biologics Evaluation and Research (CBER), the name by which biologics went by from then to the present, and he served in this role until retirement in 1990. 

...